Alector Inc. Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates

Reuters

08/08

<a href="https://laohu8.com/S/ALEC">Alector Inc.</a> Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates

Alector Inc. has released a corporate presentation highlighting its strategic positioning in treating brain disorders. The presentation outlines Alector's progress in its late-stage clinical programs, including a pivotal Phase 3 data readout in frontotemporal dementia with a GRN gene mutation (FTD-GRN) expected by mid-Q4 2025 and the completion of Phase 2 clinical trial enrollment in Alzheimer's disease (AD), with trial completion anticipated in 2026. Alector continues to advance its innovative science with the 3R Strategy and advanced technologies focused on anti-Aβ antibody and GCase enzyme replacement therapies. The company remains well-resourced, with financial means extending into the second half of 2027 and a profit-sharing collaboration for PGRN product candidates. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief on August 07, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557959118"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557959118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557959118?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 05:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557959118","market":"us","top_or_hot":-1,"title":"Alector Inc. Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ALEC\">Alector Inc.</a> Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alector Inc. has released a corporate presentation highlighting its strategic positioning in treating brain disorders. The presentation outlines Alector's progress in its late-stage clinical programs, including a pivotal Phase 3 data readout in frontotemporal dementia with a GRN gene mutation (FTD-GRN) expected by mid-Q4 2025 and the completion of Phase 2 clinical trial enrollment in Alzheimer's disease (AD), with trial completion anticipated in 2026. Alector continues to advance its innovative science with the 3R <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> and advanced technologies focused on anti-Aβ antibody and GCase enzyme replacement therapies. The company remains well-resourced, with financial means extending into the second half of 2027 and a profit-sharing collaboration for PGRN product candidates. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief on August 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alector Inc. Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlector Inc. Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-08 05:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ALEC\">Alector Inc.</a> Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alector Inc. has released a corporate presentation highlighting its strategic positioning in treating brain disorders. The presentation outlines Alector's progress in its late-stage clinical programs, including a pivotal Phase 3 data readout in frontotemporal dementia with a GRN gene mutation (FTD-GRN) expected by mid-Q4 2025 and the completion of Phase 2 clinical trial enrollment in Alzheimer's disease (AD), with trial completion anticipated in 2026. Alector continues to advance its innovative science with the 3R <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> and advanced technologies focused on anti-Aβ antibody and GCase enzyme replacement therapies. The company remains well-resourced, with financial means extending into the second half of 2027 and a profit-sharing collaboration for PGRN product candidates. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief on August 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALEC","symbol_name":"Alector Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL1z3XKd:1","article_id":"2557959118","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557959118","pubTimestamp":1754600438,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alector Inc. has released a corporate presentation highlighting its strategic positioning in treating brain disorders. The presentation outlines Alector's progress in its late-stage clinical programs, including a pivotal Phase 3 data readout in frontotemporal dementia with a GRN gene mutation  expected by mid-Q4 2025 and the completion of Phase 2 clinical trial enrollment in Alzheimer's disease , with trial completion anticipated in 2026. Alector continues to advance its innovative science with the 3R Strategy and advanced technologies focused on anti-Aβ antibody and GCase enzyme replacement therapies. The company remains well-resourced, with financial means extending into the second half of 2027 and a profit-sharing collaboration for PGRN product candidates. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALEC":"Alector Inc.","BK4139":"生物科技"},"translate_title":"Alector Inc.推出有关脑部疾病治疗进展和临床计划更新的演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALEC":0.9},"content_text":"Alector Inc. Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates\n    \n\n        Alector Inc. has released a corporate presentation highlighting its strategic positioning in treating brain disorders. The presentation outlines Alector's progress in its late-stage clinical programs, including a pivotal Phase 3 data readout in frontotemporal dementia with a GRN gene mutation (FTD-GRN) expected by mid-Q4 2025 and the completion of Phase 2 clinical trial enrollment in Alzheimer's disease (AD), with trial completion anticipated in 2026. Alector continues to advance its innovative science with the 3R Strategy and advanced technologies focused on anti-Aβ antibody and GCase enzyme replacement therapies. The company remains well-resourced, with financial means extending into the second half of 2027 and a profit-sharing collaboration for PGRN product candidates. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief on August 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}